Trial ID or NCT#

NCT00928226

Status

NOT RECRUITING

Purpose

We hope to determine the maximum tolerated dose of 3 session (i.e., treatment) stereotactic radiosurgery to treat brain metastases greater than 4.2 cm3 in size. By increasing radiation dose, we will determine if there is a better outcome without greater toxicity (side effects) for patients.

Official Title

A Phase I/II Study of Fractionated Stereotactic Radiosurgery to Treat Large Brain Metastases

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Scott G. Soltys, MD
Radiation oncologist
Associate Professor of Radiation Oncology (Radiation Therapy) at the Stanford University Medical Center
Steven D. Chang, MD
Neurosurgeon, Aneurysm neurosurgeon, Cerebrovascular neurosurgeon, Pituitary tumors neurosurgeon, Stereotactic neurosurgeon, Neuro-oncologist
Robert C. and Jeannette Powell Neurosciences Professor and, by courtesy, of Otolaryngology-Head and Neck Surgery
John R. Adler, MD
Stereotactic neurosurgeon
The Dorothy and Thye King Chan Professor in Neurosurgery, Emeritus
Iris C. Gibbs, MD, FACR
Radiation oncologist, Neuro-oncologist
Professor of Radiation Oncology (Radiation Therapy) at the Stanford University Medical Center
Griffith Harsh, MD
Neurosurgeon
Professor of Neurosurgery and, by courtesy, of Otolaryngology-Head and Neck Surgery at the Stanford University Medical Center
Gordon Li, MD
Neurosurgeon
Associate Professor of Neurosurgery and, by courtesy, of Neurology and of Otolaryngology-Head and Neck Surgery at the Stanford University Medical Center

Contact us to find out if this trial is right for you.

CONTACT

Ccto-office@stanford.edu
(650) 498-7061